Education
About Us
Working with TipRanks
Follow Us
BioInvent International AB (BOVNF)
OTHER OTC:BOVNF
Earnings Data
Report Date
Aug 26, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
―Last Year’s EPS
-2.09Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Date:Apr 29, 2025
|% Change Since: 7.52%
|Next Earnings Date:Aug 26, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials and strategic collaborations, with promising data in lead compounds and strong financial reserves. However, these positives are counterbalanced by decreased net sales, increased operating costs, and significant financial losses.Company Guidance
During the BioInvent Q3 2024 earnings call, CEO Martin Welschof and CFO Stefan Ericsson provided extensive guidance on the company's development programs, highlighting several key metrics. The company reported net sales of SEK 12.8 million for Q3 2024, a decrease from SEK 26.8 million in Q3 2023, primarily due to the absence of a $1 million milestone achieved in the previous year. Operating costs increased to SEK 120 million compared to SEK 108 million in Q3 2023, partly due to higher costs associated with their BI-1607 and BI-1808 programs. The loss for Q3 2024 was reported as SEK 97.2 million. The company emphasized the promising progress of its lead compounds, including BI-1206, BI-1808, and BI-1910, with significant developments in both subcutaneous and intravenous formulations, notably in achieving complete and partial responses in clinical trials. They anticipate further data releases by the end of the year and into 2025, which could drive substantial value and strategic opportunities, including potential partnerships. BioInvent's liquid funds at the end of September amounted to SEK 979 million, providing a runway until Q1 2026, and the management expressed optimism about securing collaborations to bolster their financial position.Positive Data for Lead Compound BI-1206
The company reported additional positive data for their lead compound BI-1206, targeting FcgammaRIIB, especially for the subcutaneous formulation, with 2 complete responses, 3 partial responses, and 3 stable diseases out of 9 evaluable patients.
Progress in BI-1808 and BI-1910 Programs
BI-1808 showed 3 partial responses and 1 stable disease out of 4 evaluable patients in the CTCL cohort. BI-1910 received a Notice of Allowance and showed robust target occupancy in trials.
Successful Subcutaneous Formulation
The subcutaneous (subcu) formulation of BI-1206 showed improved activity and safety profile compared to the intravenous version, eliminating infusion-related reactions.
Strategic Collaborations
New clinical trial collaboration and supply agreements were established with Merck for BI-1607, and with AstraZeneca for BI-1206 in a triplet combination with rituximab and acalabrutinib.
Promising Anti-CTLA-4 Antibody Data
The anti-CTLA-4 antibody in combination with pembrolizumab showed tumor regression in patients who failed previous anti-PD-L1 treatment.
Strong Financial Position
The company has liquid funds of SEK 979 million, providing a financial runway until the end of Q1 2026.
BOVNF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BOVNF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 29, 2025 | $3.06 | $3.21 | +4.90% |
Feb 27, 2025 | $2.30 | $2.36 | +2.61% |
Oct 31, 2024 | $4.14 | $4.06 | -1.93% |
Aug 29, 2024 | $3.86 | $3.51 | -9.07% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does BioInvent International AB (BOVNF) report earnings?
BioInvent International AB (BOVNF) is schdueled to report earning on Aug 26, 2025, TBA Not Confirmed.
What is BioInvent International AB (BOVNF) earnings time?
BioInvent International AB (BOVNF) earnings time is at Aug 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BOVNF EPS forecast?
Currently, no data Available